Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results May 4, 2022 04:01PM
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results Mar 8, 2022 06:16AM
Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee Feb 3, 2022 07:00AM
Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates Feb 25, 2021 04:01PM
Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer Sep 14, 2020 04:30PM
View Older Stories

Aug 10, 2020 07:00AM Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
Mar 3, 2020 04:01PM Voyager Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates
Nov 6, 2019 06:22AM Voyager Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Highlights
Aug 9, 2019 07:00AM Voyager Therapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
Jun 17, 2019 01:07PM Voyager Therapeutics (VYGR) PT Doubled to $30 at Chardan Capital Markets
Jun 17, 2019 07:33AM Voyager Therapeutics (VYGR) Reports Restructured Gene Therapy Relationship with Sanofi (SNY) Genzyme; Provides Portfolio Update
Jun 17, 2019 07:30AM Voyager Therapeutics Announces Restructured Gene Therapy Relationship with Sanofi Genzyme and Portfolio Update
Jun 11, 2019 04:30PM Voyager Therapeutics to Present at the Raymond James Life Sciences & MedTech Conference
May 20, 2019 04:33PM Voyager Therapeutics (VYGR) announces retirement of Dinah Sah, Ph.D. as chief scientific officer
May 20, 2019 04:30PM Voyager Therapeutics Announces Management Updates
May 7, 2019 07:05AM Voyager Therapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights
May 6, 2019 05:44AM Neurocrine Biosciences (NBIX), Voyager Therapeutics, Inc. (VYGR) Report Phase I Results for VY-AADC in Patients with Parkinson's Disease at AAN 2019 Meetings
May 5, 2019 09:05AM Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
May 5, 2019 09:05AM Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson’s Disease at the American Academy of Neurology Annual Meeting
Apr 29, 2019 07:04AM Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
Apr 15, 2019 12:25PM Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
Apr 3, 2019 04:15PM Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c)(4)
Apr 2, 2019 04:15PM Voyager Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Mar 28, 2019 04:15PM Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
Feb 26, 2019 04:05PM Voyager Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
Feb 22, 2019 08:01AM AbbVie (ABBV), Voyager Therapeutics (VYGR) Enter Pact to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies
Feb 22, 2019 08:00AM AbbVie and Voyager Therapeutics Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies
Feb 22, 2019 08:00AM Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies
Feb 19, 2019 08:00AM Voyager Therapeutics to Present at Upcoming Investor Conferences
Feb 18, 2019 08:00AM Voyager Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
Jan 29, 2019 07:07AM Neurocrine Biosciences (NBIX) and Voyager Therapeutics (VYGR) Announces Pact for Parkinson’s Disease and Friedreich’s Ataxia
Jan 29, 2019 07:00AM Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia
Jan 22, 2019 07:05AM Voyager Therapeutics Appoints Robert Hesslein as General Counsel
Jan 15, 2019 07:03AM Voyager Therapeutics to Appoint Omar Khwaja, M.D., Ph.D., as Chief Medical Officer
Jan 7, 2019 07:10AM Voyager Therapeutics (VYGR) Announces Updates for VY-AADC Clinical Program for Parkinson’s Disease
Jan 7, 2019 07:07AM Voyager Therapeutics Provides Updates for VY-AADC Clinical Program for Parkinson’s Disease
Dec 17, 2018 07:10AM Voyager Therapeutics Joins Michael J. Fox Foundation Initiatives and Education Campaigns to Accelerate the Development of New therapies and a Cure for Parkinson’s Disease
Dec 10, 2018 07:18AM Voyager Therapeutics (VYGR) Reports First Patient Dosing in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy
Dec 10, 2018 07:10AM Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease
Nov 29, 2018 07:06AM Voyager Therapeutics (VYGR) Announces Strategic Manufacturing Collaborations with Brammer Bio & Fujifilm Diosynth Biotechnologies
Nov 29, 2018 07:04AM Voyager Therapeutics Enters into Strategic Manufacturing Collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies
Nov 19, 2018 04:21PM Voyager Therapeutics to Present at the Evercore ISI Healthcare Conference
Nov 7, 2018 05:28PM Voyager Therapeutics (VYGR) Reports Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
Nov 7, 2018 04:10PM Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights
Nov 7, 2018 04:10PM Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
Oct 31, 2018 06:30AM Voyager Therapeutics to Host Third Quarter 2018 Financial Results and Corporate Highlights Conference Call
Oct 16, 2018 07:05AM Voyager Therapeutics (VYGR) Announces Preclinical Data for Huntington’s Disease and Amyotrophic Lateral Sclerosis Programs at ESGCT
Oct 16, 2018 07:03AM Voyager Therapeutics Announces Preclinical Data for Huntington’s Disease and Amyotrophic Lateral Sclerosis Programs at the Congress of the European Society of Gene and Cell Therapy
Aug 28, 2018 11:53AM Voyager Therapeutics to Present at Investor Conferences in September
Aug 7, 2018 04:07PM Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights
Aug 2, 2018 08:26AM Voyager Therapeutics to Present at Investor Conferences in August
Jul 31, 2018 04:59PM Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights Conference Call
Jul 17, 2018 07:05AM Voyager Therapeutics (VYGR) Announces Feedback from Type C Meeting with FDA on Development Path for VY-AADC for Parkinson's Disease
Jul 17, 2018 07:04AM Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson’s Disease and Provides Clinical Update
Jun 28, 2018 04:32PM Voyager Therapeutics (VYGR) Names Andre Turenne as President & CEO
View Older Stories